Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy

FierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B

LabiotechHow Daiichi Sankyo aims to become a top five oncology player by 2035

PharmaVoiceAmid a flurry of biotech deals, China looks to keep innovation at home

CellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptation

Endpoints NewsEthyreal lands $101M to treat both Graves' and thyroid eye disease

Endpoints NewsSanofi to mull riliprubart’s future after stopping late-stage nerve disease study

FierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechs

FierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue

LabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurology

Endpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drug

eLifeAltered cognitive processes shape tactile perception in autism

eLifeCell size modulates ferroptosis susceptibility